Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Pyrogallol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.44 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.71 |
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | HPGD | P15428 | 4/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.71 |
| ▸ | CDK2 | P24941 | 3/20 | 0.71 |
| ▸ | CA2 | P00918 | 3/20 | 0.71 |
| ▸ | EGFR | P00533 | 2/20 | 0.71 |
| ▸ | FYN | P06241 | 2/20 | 0.71 |
| ▸ | MMP9 | P14780 | 2/20 | 0.71 |
| ▸ | RECQL | P46063 | 2/20 | 0.71 |
| ▸ | CA1 | P00915 | 2/20 | 0.71 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.71 |
| ▸ | MMP2 | P08253 | 1/20 | 0.71 |
| ▸ | MMP8 | P22894 | 1/20 | 0.71 |
| ▸ | CA6 | P23280 | 1/20 | 0.71 |
| ▸ | MMP12 | P39900 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrogallol SCHEMBL28963965 | 0.97 | ALDH1A1 (0.67) | ALDH1A1ALOX15HSD17B10LMNAHPGD | |
| Pyrogallol SCHEMBL209233 | 0.89 | ALDH1A1 (0.63) | ALDH1A1ALOX15HSD17B10LMNAHPGD | |
| Pyrogallol SCHEMBL214769 | 0.89 | ALDH1A1 (0.63) | ALDH1A1ALOX15HSD17B10LMNAHPGD | |
| Pyrogallol SCHEMBL28234833 | 0.88 | CA2 (0.71) | ALDH1A1ALOX15HSD17B10LMNAHPGD | |
| Pyrogallol SCHEMBL16714223 | 0.85 | ALDH1A1 (0.57) | ALDH1A1ALOX15HSD17B10LMNAHPGD | |
| Pyrogallol SCHEMBL2900972 | 0.85 | ALDH1A1 (0.57) | ALDH1A1ALOX15HSD17B10LMNAHPGD | |
| Pyrogallol SCHEMBL704091 | 0.85 | ALDH1A1 (0.57) | ALDH1A1ALOX15HSD17B10LMNAHPGD | |
| Pyrogallol SCHEMBL1056082 | 0.85 | ALDH1A1 (0.57) | ALDH1A1ALOX15HSD17B10LMNAHPGD | |
| Pyrogallol SCHEMBL3532 | 0.84 | — | — | |
| Pyrogallol SCHEMBL170157 | 0.84 | ALDH1A1 (1.00) | ALDH1A1ALOX15HSD17B10LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| US-20200138894-A1 | FLAVONOID COMPOSITIONS AND METHODS OF USE | BERKLEY, LLC | 2020-05-07 | — | — | US | claimed |
| US-10441621-B2 | Flavonoid compositions and methods of use | REOXCYN, LLC (US) | 2019-10-15 | — | — | US | claimed |
| CN-106654200-A | Electrode material, preparation method and application thereof | 南方科技大学 | 2017-05-10 | — | — | CN | claimed |
| US-20170106036-A1 | FLAVONOID COMPOSITIONS AND METHODS OF USE | BERKLEY, LLC | 2017-04-20 | — | — | US | claimed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | disclosed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | disclosed |
| US-12274730-B2 | Flavonoid compositions and methods of use | BERKLEY, LLC (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4457513-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2024-11-06 | — | — | EP | disclosed |
| CN-118435054-A | Compositions and methods for diagnosing and treating chronic kidney disease | 雀巢产品有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20240257973-A1 | DISEASE SPECTRUM CLASSIFICATION | PATIENTSLIKEME LLC (US) | 2024-08-01 | — | — | US | disclosed |
| US-11929171-B2 | Methods for evaluation and treatment of glycemic dysregulation and atherosclerotic cardiovascular disease and applications thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-12 | — | — | US | disclosed |
| US-20200230193-A1 | FLAVONOID COMPOSITIONS AND METHODS OF USE | BERKLEY, LLC | 2020-07-23 | — | — | US | disclosed |
| US-20200227166-A1 | Methods for Evaluation and Treatment of Glycemic Dysregulation and Atherosclerotic Cardiovascular Disease and Applications Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200138894-A1 | FLAVONOID COMPOSITIONS AND METHODS OF USE | BERKLEY, LLC | 2020-05-07 | — | — | US | disclosed |
| US-10441621-B2 | Flavonoid compositions and methods of use | REOXCYN, LLC (US) | 2019-10-15 | — | — | US | disclosed |
| US-20170370954-A1 | Biomarkers for Fatty Liver Disease and Methods Using the Same | METABOLON, INC. | 2017-12-28 | — | — | US | disclosed |
| EP-3221463-A1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20170106036-A1 | FLAVONOID COMPOSITIONS AND METHODS OF USE | BERKLEY, LLC | 2017-04-20 | — | — | US | disclosed |
| WO-2016081534-A1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | METABOLON, INC. (US) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | MAOA 1233/4885MAOB 1784/4885ALDH1A1 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.